Akero Therapeutics Stock Alpha and Beta Analysis
| AKRO Stock | USD 46.10 0.31 0.67% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Akero Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Akero Therapeutics over a specified time horizon. Remember, high Akero Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Akero Therapeutics' market risk premium analysis include:
Beta 1.59 | Alpha (0.26) | Risk 2.58 | Sharpe Ratio (0.05) | Expected Return (0.14) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Akero Therapeutics Backtesting, Akero Therapeutics Valuation, Akero Therapeutics Correlation, Akero Therapeutics Hype Analysis, Akero Therapeutics Volatility, Akero Therapeutics History and analyze Akero Therapeutics Performance. Akero Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Akero Therapeutics market risk premium is the additional return an investor will receive from holding Akero Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Akero Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Akero Therapeutics' performance over market.| α | -0.26 | β | 1.59 |
Akero Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Akero Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Akero Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Akero Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Akero Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Akero Therapeutics shares will generate the highest return on investment. By understating and applying Akero Therapeutics stock market price indicators, traders can identify Akero Therapeutics position entry and exit signals to maximize returns.
Akero Therapeutics Return and Market Media
The median price of Akero Therapeutics for the period between Sun, Jul 6, 2025 and Sat, Oct 4, 2025 is 48.19 with a coefficient of variation of 5.98. The daily time series for the period is distributed with a sample standard deviation of 2.89, arithmetic mean of 48.28, and mean deviation of 2.31. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 1342 shares by Catriona Yale of Akero Therapeutics at 53.474 subject to Rule 16b-3 | 07/16/2025 |
2 | Viking Therapeutics Gears Up for Q2 Earnings Heres What to Expect | 07/21/2025 |
3 | Disposition of 400 shares by Cheng Andrew of Akero Therapeutics at 49.435 subject to Rule 16b-3 | 08/11/2025 |
4 | Does Akero Therapeutics Have the Potential to Rally 59.14 percent as Wall Street Analysts Expect | 08/27/2025 |
5 | Disposition of 5161 shares by Timothy Rolph of Akero Therapeutics at 6.364 subject to Rule 16b-3 | 09/08/2025 |
6 | Disposition of 13022 shares by Cheng Andrew of Akero Therapeutics at 6.364 subject to Rule 16b-3 | 09/10/2025 |
7 | Disposition of 1796 shares by Cheng Andrew of Akero Therapeutics at 43.02 subject to Rule 16b-3 | 09/11/2025 |
8 | Insider Selling Akero Therapeutics COO Sells 586 Shares of Stock | 09/15/2025 |
9 | AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL Kahn Swick Foti, LLC Investigates the Officers and Directors of Akero Therapeuti... | 09/18/2025 |
10 | Will Legal Scrutiny of Akero Therapeutics Leadership Reshape Confidence in Its Long-Term Strategy | 09/22/2025 |
11 | LLY Gets EU Approval for Alzheimers Drug FDA Nod to Cancer Therapy | 09/26/2025 |
12 | Disposition of 12500 shares by Young Jonathan of Akero Therapeutics at 21.1 subject to Rule 16b-3 | 10/01/2025 |
13 | Jonathan Young Sells 12,500 Shares of Akero Therapeutics Stock - MarketBeat | 10/03/2025 |
About Akero Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Akero or other stocks. Alpha measures the amount that position in Akero Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 18.61 | 29.27 | 19.38 | 14.62 | Net Debt To EBITDA | 2.15 | 1.4 | 1.07 | 2.08 |
Akero Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Akero Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akero Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Akero Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Akero Therapeutics. Please utilize our Beneish M Score to check the likelihood of Akero Therapeutics' management manipulating its earnings.
| 15th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Akero Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Akero Therapeutics Backtesting, Akero Therapeutics Valuation, Akero Therapeutics Correlation, Akero Therapeutics Hype Analysis, Akero Therapeutics Volatility, Akero Therapeutics History and analyze Akero Therapeutics Performance. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Akero Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.